2013-03-20 18:06:56 -
Live presentation at 8 AM ET in New York City
Webcast at 1 PM CET/12 PM GMT, www.glpg.com, +32 2290 1608
Mechelen, Belgium; 20 March 2013 - Galapagos NV (Euronext: GLPG) will host its
annual R&D update in New York City on Wednesday, 27 March.
Formal proceedings will begin at 8:00 am Eastern Time/1:00 pm Central European
Time and end at approximately 10:00 am ET/3:00 pm CET. The event will include
presentations from Onno van de Stolpe, CEO, and Dr Piet Wigerinck, CSO, who will
discuss the progress in the portfolio of novel mode-of-action medicines, and
include the plans for the upcoming Phase 2b trial of its selective JAK1
inhibitor GLPG0634.
The presentation
will be webcast live and archived on Galapagos' website for one
year. To access the live webcast, go to www.glpg.com or click here, call number
+32-2290-1608. To attend this meeting in person, please contact Elizabeth
Goodwin at
ir@glpg.com.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of four clinical, six pre-clinical, and 30 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about to
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-
licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974 is the
first inhibitor of GPR43 to be evaluated clinically for the treatment of IBD;
this program will start a Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has over 800 employees and operates facilities in five countries, with
global headquarters in Mechelen, Belgium. Further information at: www.glpg.com
Contact
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks,"
"estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Galapagos to host annual R&D update on 27 March:
hugin.info/133350/R/1686702/553042.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1686702]
